What is the appropriate starting dose, titration schedule, maximum dose, monitoring parameters, and contraindications for methylphenidate extended‑release?

Methylphenidate Extended-Release: Dosing and Clinical Management

For methylphenidate extended-release (ER) in ADHD, start with 5 mg twice daily in children ≥6 years or 5 mg once daily for adults, titrate by 5-10 mg weekly based on response, with a maximum dose of 60 mg/day regardless of formulation. 1, 2

Starting Dose

Children ≥6 years:

• Begin with 5 mg twice daily (before breakfast and lunch) 1, 2
• For children <25 kg, maximum titration should not exceed 35 mg/day 1
• For children <45 lb (20 kg), omit the 15-20 mg dose week during titration 1

Adults:

• Start with 5 mg once or twice daily 1
• Administer 30-45 minutes before meals 2
• Average therapeutic dose is 20-30 mg daily 2

Extended-release formulations can be initiated by converting the total daily immediate-release dose to a single morning dose, or by starting de novo at lower doses 1

Titration Schedule

Weekly titration protocol 1:

• Week 1: 5 mg (baseline assessment with ADHD rating scales, blood pressure, pulse, height, weight)
• Week 2: 10 mg (visit or phone contact with symptom and side effect monitoring)
• Week 3: 15 mg (visit or phone contact)
• Week 4: 20 mg (physician visit to review all scales and select optimal dose)

Titration increments:

• Increase by 5-10 mg weekly in children 1
• Increase by 5-10 mg weekly in adults until symptoms controlled 1

Alternative "forced titration": Patient takes all four dosages (5,10,15,20 mg) with each dose lasting 1 week, then clinician selects the dose producing most benefit with fewest side effects 1

Maximum Dose

The maximum recommended daily dose is 60 mg regardless of formulation 1, 2. However:

• Some adults may require up to 1.0 mg/kg/day or 65 mg total daily dose to cover a longer day 1
• Higher doses require clear documentation that symptoms could not be controlled at lower doses and are not producing side effects (weight loss, blood pressure increase, agitation) 1
• Monitor for signs of tolerance at higher doses 1

Monitoring Parameters

Baseline assessment 1, 2:

• ADHD symptom rating scales (from teachers and parents for children; from patient and significant other for adults)
• Blood pressure and pulse
• Height and weight
• Screen for substance use history (especially in adolescents)
• Screen for risk factors for manic episodes
• Assess family history and evaluate for tics or Tourette's syndrome
• Electrocardiogram and biological check-up if indicated

Ongoing monitoring 1, 2:

• Weekly during titration: ADHD rating scales, side effects assessment
• At each dose increase: Blood pressure, pulse (can be done via phone contact)
• Every 3 months: Height and weight in pediatric patients (watch for growth suppression)
• Regularly: Monitor for emergence of tics, psychiatric symptoms (agitation, psychosis, mania), cardiovascular symptoms
• Adolescents: Monitor for signs of medication misuse or diversion

Common side effects to monitor 3, 2:

• Agitation and insomnia (most common—dose early in day to minimize)
• Decreased appetite and weight loss
• Tachycardia and palpitations
• Headache
• Anxiety and irritability
• Abdominal pain, nausea, dry mouth

Contraindications

Absolute contraindications 3, 2:

• Known hypersensitivity to methylphenidate
• Concurrent MAOI use or within 14 days of MAOI discontinuation
• Uncontrolled hypertension
• Underlying coronary artery disease
• Serious cardiac arrhythmias or tachyarrhythmias
• Known structural cardiac abnormalities or cardiomyopathy

Relative contraindications/special precautions 2:

• Open-angle glaucoma or abnormally increased intraocular pressure (prescribe only if benefit outweighs risk)
• Risk factors for acute angle closure glaucoma (requires ophthalmology evaluation)
• History of tics or Tourette's syndrome (assess before initiating; discontinue if worsening)
• Psychiatric conditions (screen for bipolar disorder, psychosis risk before initiating)
• Active substance use disorder (requires subspecialist consultation)

Clinical Pearls

Timing considerations:

• Administer extended-release formulations in the morning to minimize insomnia 3
• Sustained-release formulations provide 4-6 hours of action; newer formulations provide up to 8 hours 3
• For adolescents who drive, consider longer-acting or late-afternoon short-acting doses for symptom control while driving 4

Formulation flexibility:

• Extended-release capsules can be sprinkled in food 3
• Different ER formulations have varying IR/MR ratios (15-50% immediate-release component) allowing for individualized time-action profiles 1

Special populations:

• Preschool children (4-5 years) metabolize methylphenidate more slowly; use lower starting doses with smaller increments if medication is deemed necessary 4
• Only children with moderate-to-severe ADHD dysfunction unresponsive to behavioral therapy should receive medication at this age 4